PURPOSE: Partial cystectomy (PC) remains a viable alternative to radical cystectomy (RC) for management of invasive bladder cancer in approximately 5% of patients. We used a population-based database to examine practice patterns and recurrence after partial cystectomy. MATERIALS AND METHODS: We obtained billing records of all partial and radical cystectomies performed for bladder cancer in Quebec from 1983 until 2005. Analysis included age, gender, year of surgery, surgeon's age, hospital type, preoperative and postoperative visits with accompanying diagnoses and dates of recurrences salvage RC, and death. RESULTS: A total of 714 (30.4%) patients with invasive bladder cancer underwent PC. Majority of PC (65%) were performed in non-academic institutions. Pelvic lymphadenectomy was performed in only 163 patients (23%) and concomitant ureteral reimplantation was performed in 89 patients (13%). Of 714 patients, 52 (23.7%) required a salvage RC. Median time from PC to salvage RC was 17.6 months (range 1-240 months), respectively. Patients who underwent PC had similar 5-year overall survival compared with patients who underwent upfront RC (49.8% vs. 51%, p = 0.21). CONCLUSIONS: Rate of PC for invasive bladder cancer is significantly higher than expected. Pelvic lymphadenectomy is underutilized in bladder cancer patients treated with PC. Whether prevalent use of PC is due to less stringent selection criteria remains unknown. Since late recurrence is not uncommon, lifelong follow-up is recommended.
PURPOSE: Partial cystectomy (PC) remains a viable alternative to radical cystectomy (RC) for management of invasive bladder cancer in approximately 5% of patients. We used a population-based database to examine practice patterns and recurrence after partial cystectomy. MATERIALS AND METHODS: We obtained billing records of all partial and radical cystectomies performed for bladder cancer in Quebec from 1983 until 2005. Analysis included age, gender, year of surgery, surgeon's age, hospital type, preoperative and postoperative visits with accompanying diagnoses and dates of recurrences salvage RC, and death. RESULTS: A total of 714 (30.4%) patients with invasive bladder cancer underwent PC. Majority of PC (65%) were performed in non-academic institutions. Pelvic lymphadenectomy was performed in only 163 patients (23%) and concomitant ureteral reimplantation was performed in 89 patients (13%). Of 714 patients, 52 (23.7%) required a salvage RC. Median time from PC to salvage RC was 17.6 months (range 1-240 months), respectively. Patients who underwent PC had similar 5-year overall survival compared with patients who underwent upfront RC (49.8% vs. 51%, p = 0.21). CONCLUSIONS: Rate of PC for invasive bladder cancer is significantly higher than expected. Pelvic lymphadenectomy is underutilized in bladder cancerpatients treated with PC. Whether prevalent use of PC is due to less stringent selection criteria remains unknown. Since late recurrence is not uncommon, lifelong follow-up is recommended.
Authors: A B Einstein; M Wolf; K R Halliday; G J Miller; M Hafermann; B A Lowe; F J Meyers; J T Leimert; E D Crawford Journal: Urology Date: 1996-05 Impact factor: 2.649
Authors: Wassim Kassouf; David Swanson; Ashish M Kamat; Dan Leibovici; Arlene Siefker-Radtke; Mark F Munsell; H Barton Grossman; Colin P N Dinney Journal: J Urol Date: 2006-06 Impact factor: 7.450
Authors: Jeffrey M Holzbeierlein; Ernesto Lopez-Corona; Bernard H Bochner; Harry W Herr; S Machele Donat; Paul Russo; Guido Dalbagni; Pramod C Sogani Journal: J Urol Date: 2004-09 Impact factor: 7.450
Authors: Ross J Mason; Igor Frank; Bimal Bhindi; Matthew K Tollefson; R Houston Thompson; R Jeffrey Karnes; Robert Tarrell; Prabin Thapa; Stephen A Boorjian Journal: World J Urol Date: 2017-09-14 Impact factor: 4.226
Authors: Wassim Kassouf; Armen Aprikian; Fred Saad; Rodney H Breau; Girish Kulkarni; David M Guttman; Ken Bagshaw; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Fadi Brimo; Peter Chung; Darrel Drachenberg; Yves Fradet; Niels Jacobsen; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Alex Zlotta; Neil Fleshner; D Robert Siemens; Peter C Black Journal: Can Urol Assoc J Date: 2018-03-19 Impact factor: 1.862
Authors: Michael J Leveridge; D Robert Siemens; Jason P Izard; Xuejiao Wei; Christopher M Booth Journal: Can Urol Assoc J Date: 2017-11-01 Impact factor: 1.862
Authors: Izak Faiena; Viktor Dombrovskiy; Christopher Koprowski; Eric A Singer; Thomas L Jang; Robert E Weiss Journal: Can J Urol Date: 2014-12 Impact factor: 1.344